Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to $6.8 million.

  • Orchestra BioMed Holdings' Accumulated Expenses fell 2.80% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 2.80%. This contributed to the annual value of $6.1 million for FY2024, which is 18.16% up from last year.
  • According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Accumulated Expenses is $6.8 million, which was up 2.81% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Accumulated Expenses registered a high of $7.0 million during Q3 2024, and its lowest value of $202,931 during Q1 2022.
  • Its 3-year average for Accumulated Expenses is $5.1 million, with a median of $5.1 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Orchestra BioMed Holdings' Accumulated Expenses was 1,504.49% (2023), while the steepest drop was 4.22% (2023).
  • Quarterly analysis of 4 years shows Orchestra BioMed Holdings' Accumulated Expenses stood at $5.4 million in 2022, then decreased by 4.22% to $5.1 million in 2023, then increased by 18.16% to $6.1 million in 2024, then declined by 2.80% to $6.8 million in 2025.
  • Its Accumulated Expenses was $6.8 million in Q3 2025, compared to $6.7 million in Q2 2025 and $5.4 million in Q1 2025.